# Rediscovery Life Sciences AKI

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rediscovery-life-sciences-aki

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.rediscoveryls.com
- Total disclosed funding: $4.5M
- Latest round: Series B (Sep 23, 2020)
- Investors on record: 2

## About

Founded in 2016 by its CSO, Rick Schnellman, Daniel Behr, Dennis Underwood, and Ed Kahn, and based in Massachusetts, US, Rediscovery Life Sciences AKI LLC, develops a rapid and cost-effective treatment to repurpose existing drugs with strong safety profiles. In September 2020, Rediscovery Life Sciences, LLC raised USD 4.5 million in series B funding co-led by investors, Orlando Health Ventures, and Rex Health Ventures. As of 2022, the company is led by its chairman, Patrick Donnelly, and Richard Shea acts as the CEO of the company.

The company develops medicines with less risk through drug repurposing for the treatment of acute kidney injury. The company develops suramin to treat African sleeping sickness and is evaluating the effect of suramin in diuretic-resistant AKI patients.

## Funding rounds

- Series B, Sep 23, 2020, $4.5M — Rex Health Ventures, Orlando Health Ventures

## Investors

- Rex Health Ventures (https://capitalatlas.ai/funds/rex-health-ventures) — Series B
- Orlando Health Ventures — Series B